Trelanserin (INN; developmental code name SL 65.0472) is a dual serotonin 5-HT1B receptor antagonist and serotonin 5-HT2A receptor antagonist which was under development for the treatment of peripheral arterial occlusive disorders and thrombosis but was never marketed.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.